A new scaffold to help heal severe skin injuries faster
Official title: DermiSphere™: An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery, CRP
Funded at Fesariustherapeutics, INC. · NIH-10907617 · Data updated 2026-11-12
This study is testing a new product called DermiSphere™ that helps people with severe skin loss, like from burns, heal faster by encouraging their own skin cells to grow back and create new skin.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fesariustherapeutics, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $396,663 |
| NIH project number | 5SB1AR076301-05 |
| Project ID | NIH-10907617 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from full thickness skin loss due to burns or other severe injuries.
✕Less likely to help
Patients with superficial skin injuries or those who do not require reconstructive surgery may not benefit from this research.
What this research studies
This research focuses on developing DermiSphere™, an advanced dermal regeneration scaffold designed to improve healing in patients with full thickness skin loss, such as severe burns. The approach involves creating a cell-free scaffold that encourages the body's own cells to infiltrate and form new dermal tissue, significantly speeding up the healing process. By addressing the limitations of current treatments, this innovative scaffold aims to enhance the quality and speed of recovery for patients undergoing reconstructive surgery.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective healing for patients with severe skin injuries.
How similar studies have gone: Previous research has shown promise in using dermal replacement scaffolds, but DermiSphere™ aims to introduce novel features that could enhance outcomes significantly.
Where this research is happening
-
Fesariustherapeutics, INC.
New York, United States Active
Researchers
- Principal investigator: Sapir Lekhovitser, Yulia — Fesariustherapeutics, INC.
- Study coordinator: Sapir Lekhovitser, Yulia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.